Working… Menu

Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03524820
Recruitment Status : Recruiting
First Posted : May 15, 2018
Last Update Posted : September 11, 2019
Merck Serono International SA
Information provided by (Responsible Party):
Hadassah Medical Organization

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 31, 2022
Estimated Study Completion Date : February 28, 2023